1 recruiting, 1 withdrawn. 2 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 2 | Recruiting 1, Withdrawn 1 |
Follow SP-420: new trials by email Literature Review of SP-420 trials Research Report on SP-420
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| A Trial Testing SP-420 in Subjects With Transfusion-dependent β-thalassemia or Low-risk Myelodysplastic Syndromes SP-420 - Beta Thalassemia Major Anemia, Myelodysplastic Syndrome | Phase 2 | Recruiting | Pharmacosmos A/S | 90 | 2023-09-04 | 2025-09-24 |
| SP-420 in Subjects With Transfusion-dependent Beta-Thalassemia or Other Rare Anemias SP-420 - Iron Overload, Beta-Thalassemia | Phase 2 | Withdrawn | Abfero Pharmaceuticals, Inc | 2020-08-01 | 2020-10-05 |
Iron Overload (1) · Myelodysplastic Syndromes (1) · beta-Thalassemia (1)
Abfero Pharmaceuticals, Inc (1) · Pharmacosmos A/S (1)
Canada (1) · Denmark (1) · Lebanon (1) · Thailand (1) · Turkey (Türkiye) (1)